The federal government will begin shipping „tens of thousands“ of courses of remdesivir early this week and will decide where the medicine goes, according to Daniel O’Day, chairman and CEO of Gilead Sciences, the maker of the investigational drug.
The federal government will begin shipping „tens of thousands“ of courses of remdesivir early this week and will decide where the medicine goes, according to Daniel O’Day, chairman and CEO of Gilead Sciences, the maker of the investigational drug.
In early results from a trial sponsored by the National Institutes of Health, remdesivir was found to shorten the duration of illness in patients with severe Covid-19, but it had no statistically significant effect on whether patients died.
„We intend to get [remdesivir] to patients in the early part of this next week, beginning to work with the government, which will determine which cities are most vulnerable and where the patients are that need this medicine,“ O’Day said on CBS‘ „Face the Nation“ this weekend.
CNN has reached out to the US Department of Health and Human Services for comment on how the drugs will be distributed.
Government will begin shipping ‚tens of thousands of treatment courses‘
Read More
Earlier this week, the US Food and Drug Administration authorized remdesivir for emergency use in patients with severe Covid-19, and Gilead previously announced it would donate its existing supply of the drug.
Remdesivir drug shows promise — but it is far from a coronavirus cure
„What we will do is provide that donation to the US government, and they will determine, based upon things like ICU beds, where the course of the epidemic is in the United States.
